补肺化瘀汤联合白蛋白紫杉醇+顺铂化疗方案对晚期肺鳞癌患者鳞状细胞癌抗原、辅助性T淋巴细胞17/调节性T淋巴细胞水平的影响

Effect of Bufei Huayu Decoction with TP regimen on squamous cell carcinoma antigen and T helper cell 17/regulatory T cells of patients with lung squamous cell carcinoma

目的观察补肺化瘀汤联合白蛋白紫杉醇+顺铂化疗方案对晚期肺鳞癌患者鳞状细胞癌抗原(SCCAg)、辅助性T淋巴细胞17(Th17)/调节性T淋巴细胞(Treg)水平的影响。方法将78例晚期肺鳞癌患者按照随机数字表法分为2组,对照组39例予白蛋白紫杉醇+顺铂化疗方案治疗,治疗组39例在对照组治疗基础上予补肺化瘀汤治疗。2组均21 d为1个化疗周期,共治疗3个化疗周期。比较2组治疗前后中医症状评分、外周血Th17和Treg含量、血清SCCAg水平及卡氏功能状态评分(KPS),并统计2组疗效。结果治疗组总有效率20.51%(8/39),对照组总有效率5.13%(2/39),治疗组疗效优于对照组(P<0.05)。2组治疗后中医症状各项评分均较本组治疗前降低(P<0.05),且治疗组治疗后均低于对照组(P<0.05)。2组治疗后Th17水平、Th17/Treg均较本组治疗前升高(P<0.05),Treg水平均降低(P<0.05),且治疗组治疗后Th17水平、Th17/Treg均高于对照组(P<0.05),Treg水平低于对照组(P<0.05)。2组治疗后血清SCCAg水平均较本组治疗前降低(P<0.05),且治疗组治疗后低于对照组(P<0.05)。2组治疗后KPS均较本组治疗前升高(P<0.05),且治疗组治疗后高于对照组(P<0.05)。结论补肺化瘀汤联合白蛋白紫杉醇+顺铂化疗方案可提高晚期肺鳞癌患者临床疗效,改善临床症状和体征,降低血清肿瘤标志物含量,并调节Th17/Treg水平,改善患者生活质量。

Objective To observe the effect of Bufei Huayu Decoction with a combination of paclitaxel and cisplatin chemotherapy(TP)therapy for the levels of squamous cell carcinoma antigen(SCCAg)and T helper cell 17(Th17)/regulatory T cells(Treg)of patients with lung squamous cell carcinoma(LSCC).Methods Totally 78 patients with LSCC were randomly divided into the treatment group(n=39)and the control group(n=39),all patients were managed by TP regimen,and those in the treatment group were additionally treated with Bufei Huayu Decoction.The treatment continued for 3 chemotherapy cycles(1 chemotherapy cycle for 21 days),the aim was to compare traditional Chinese medicine(TCM)syndrome score,peripheral blood Th17,Treg levels,serum SCCAg,Karnofsky performance score(KPS);the curative effect was assessed.Results The overall effective rate in the treatment group and the control group was 20.51%(8/39)and 5.13%(2/39),respectively,the curative effect being better in the treatment group than the control group(P<0.05).After treatment,TCM symptom scores in groups were decreased(P<0.05),the treatment group was lower than the control group(P<0.05);Th17,Th17/Treg in groups were increased(P<0.05),which were higher in the treatment group than in the control group(P<0.05);Treg in groups was decreased(P<0.05),the treatment group was more common(P<0.05);serum SCCAg in groups was decreased(P<0.05),improvement of which in the treatment group was significantly better(P<0.05);KPS in groups was increased(P<0.05),the treatment group was more prevalent(P<0.05).Conclusion For patients with LSCC,Bufei Huayu Decoction with TP regimen can improve clinical efficacy and the quality-of-life,it not only improves clinical symptoms and signs,but also reduces serum tumor marker levels and regulates Th17/Treg levels.